SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mok, M
Right arrow Articles by Lau, C S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mok, M
Right arrow Articles by Lau, C S
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Intestinal pseudo-obstruction in systemic lupus erythematosus: an uncommon but important clinical manifestation

M Mok

R W S Wong

C S Lau

Division of Rheumatology, University Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Objectives: To document intestinal pseudo-obstruction (IpsO) as a recognised clinical manifestation of systemic lupus erythematosus (SLE) and a possible new clinical entity with its apparent association with ureterohydronephrosis.

Methodology: We report six lupus patients who presented with IpsO and review 12 other cases from an English literature search. IpsO is defined as the presence of clinical features suggestive of intestinal obstruction but without organic obstruction, namely absence of bowel sounds, presence of multiple fluid levels on plain abdominal X-rays and exclusion of organic obstruction by imaging or surgical procedure. Other clinical characteristics related to the underlying lupus, serological and histological findings, treatment modalities and outcomes of these patients were reviewed.

Results: All 18 patients fulfilled the ACR revised classification criteria for SLE. None showed any clinical features of scleroderma or overlap syndrome. The mean age of onset of IpsO was 29.0 (15-47) y. The female to male ratio was 16: 2. Nine patients had IpsO as the initial presentation of their underlying lupus. Coexisting lupus involvement of other organ systems included glomerulonephritis (n = 7), thrombocytopenia (n = 5) and cerebral lupus (n = 3). The serology data and autoantibody profile of some of the previously reported patients were incomplete. In our series, anti-Ro antibody was positive in 5=6 while anti-RNP was found in 1=6 patients only. All our patients had active lupus serology at presentation. 17=18 patients required the use of high dose systemic corticosteroid therapy while one patient responded to topical adrenocorticotrophin hormone treatment. Response was good and was observed early after commencement. Azathioprine was used as maintenance therapy in 6=18 patients with good effects. An apparent association with the presence of bilateral ureterohydronephrosis was found in 12=18 patients. These patients presented with dysuria without positive bacterial culture though features of chronic interstitial cystitis were not invariably found in these patients.

Conclusion: IpsO is an uncommon but important manifestation of SLE. The underlying pathology is not fully understood but it may be related to immune complex deposition. The finding of coexisting ureterohydronephrosis suggests that there may also be a central smooth muscle motility problem of neuropathic or myogenic pathophysiology which may or may not be secondary to vasculitis. Early recognition and treatment of IpsO in SLE is important.

Key Words: interstitial cystitis • intestinal vasculitis • dysmotility • paralytic ileus • serositis • vasculopathy

Lupus, Vol. 9, No. 1, 11-18 (2000)
DOI: 10.1177/096120330000900104


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
J Pardos-Gea, J Ordi-Ros, A Selva, J Perez-Lopez, E Balada, and M Vilardell
Chronic intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus
Lupus, April 1, 2005; 14(4): 328 - 330.
[Abstract] [PDF]


Home page
LupusHome page
A Alexopoulou, A Andrianakos, and S P Dourakis
Intestinal pseudo-obstruction and ureterohydronephrosis as the presenting manifestations of relapse in a lupus patient
Lupus, December 1, 2004; 13(12): 954 - 956.
[Abstract] [PDF]


Home page
LupusHome page
M.-Y. Chen, K.-L. Lee, P.-N. Hsu, C.-S. Wu, and C.-H. Wu
Is there an ethnic difference in the prevalence of lupus cystitis? A report of six cases
Lupus, April 1, 2004; 13(4): 263 - 269.
[Abstract] [PDF]


Home page
LupusHome page
C C Mok and C S Lau
Lupus in Hong Kong Chinese
Lupus, September 1, 2003; 12(9): 717 - 722.
[Abstract] [PDF]



Advertisement